Ticker: WGS, $59.00, –0.24% (as of May 12, 2025, 4:00 PM ET)
Trigger: Director Keith Meister bought 100,000 shares @ $56.01 = $5.6M bet. That’s some confident DNA. 🧬💸

🧪 What’s GeneDx Again?

Stamford-based GeneDx specializes in genetic testing for rare diseases and pediatric conditions—think exome and genome sequencing, not 23andMe quizzes that say you're 12% Viking.

💼 Wall Street Likes What It Sees

📈 Institutional ownership: 113.20% of the float
(Yes, that’s more than 100%. Shorts and synthetics are in the building.)

🧠 Top holders:

• Casdin Capital: 12.29%

• Corvex Management: 8.67%

• BlackRock, Vanguard, Goldman Sachs... you get the picture. Big money is in the lab coat.

• Check this out for more.

🧩 Jefferies just upgraded the stock to “Buy” with an $80 price target. Do they know something? Maybe. Or maybe they like genomes.

⚡ So Why Did the Stock Collapse 43%? (After Great News?!)

That’s the $5.6 million question. Here's what GeneDx just reported:

📊 Q1 2025 Highlights (aka "The Good Stuff")

• Revenue: $87.1M (+42% YoY)

• Exome/Genome Revenue: $71.4M (+62% YoY)

• Adjusted Net Income: $7.7M (That’s a profit!)

• Adjusted Gross Margin: 69% (was 61%)

• Exome/Genome Volume: 20,562 tests (+24%)

• GAAP Net Loss: $6.5M ( 🤷♂️)

Interested in investing in a leading-edge biotech?
Check this out.

🧬 Business Highlights (aka "The Cool Science Stuff")

🧠 Launched ultraRapid genome testing (results in 48 hours for NICU babies)
🧠 Added cerebral palsy and IEI (Inborn Errors of Immunity) as new testing indications
🧠 Rolled out Epic Aura to integrate testing into hospital systems
🧠 Expanded Medicaid coverage to 33 states for pediatric testing
🧠 Recognized by Fast Company as one of the world’s most innovative companies

So why the stock drop? 🤷♀️
Apparently, being profitable (but not quite on a GAAP basis!), innovative, and expanding isn’t good enough for some hedge funds and other investors.
(Also, a 14.28% short interest might explain a few things.)

💡 Full-Year 2025 Guidance (Post-Fabric Genomics Deal)

• Revenue: $360M–$375M (raised!)

• Exome/genome growth: 30%+ (confirmed)

• Margins: 66%–68%

• Profitability: expected every quarter

They’re even acquiring Fabric Genomics, a move meant to expand decentralized testing (read: high-risk, maybe genius, maybe just expensive).

🧠 Translation: This Is a Smart, Small-Cap Rollercoaster

💉 The science is promising
💵 The revenue is growing
📉 The stock is moody
🧬 The future? Still being sequenced

🧪 Verdict:

GeneDx could be a genomic juggernaut in the making—or just another volatile biotech name that confuses your portfolio as much as your family tree.

Want in?
Start small. Dollar cost average.
Or better yet: risk someone else’s money. 🧃💼

⚠️ Disclaimer:

We know nothing. Genetic testing of our investing track record revealed quasi-ancestral anomalies, untraceable logic, and possible Viking heritage. 🛡️🪓⚔️ Invest accordingly. 😉

🧭 Want More Like This?

Check out our Insider Purchases Hub or Turnaround Plays Section